TrialCompass™ TCL
Back to results
Phase 2RecruitingPriority 2 · High priorityNCT02974647

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with cutaneous T-cell lymphoma (skin lymphoma). Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 10 US locations across multiple states.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Drugs / treatments
Ruxolitinib
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

NCT02974647

Phase: Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with cutaneous T-cell lymphoma (skin lymphoma). Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 10 US locations across multiple states.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

What's being tested

Drugs / treatments: Ruxolitinib

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 83 patients

Primary endpoint: disease control rate

Ages: 18 Years to —

Start date: 2016-11 | Est. completion: 2027-11

Locations

10 US sites · 10 total

Florida, Illinois, Massachusetts, New Jersey, New York

Contact

Alison Moskowitz, MD | 212-639-4839

Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)

Tags

CTCL · T-PLL · Maintenance · Newly diagnosed · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT02974647

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.